JAKARTA - PT Kalbe Genexine Biologics (KG Bio) obtained the exclusive license to produce HLX10, a recombinant human monoclonal antibody product that can be used to treat tumour, from Shanghai Henlius Biotech Inc. China. KG Bio is a joint venture between PT Kalbe Farma Tbk (KLBF) and Genexine Inc.
Quoted from a press release, Sie Djohan, Director of PT Kalbe Farma Tbk (KBLF) said that with the license, KG Bio could develop HLX 10 products for the needs of the domestic and export markets in the Southeast Asian region. "We welcome the collaboration between KGBio and Henlius to enhance research capabilities and enrich the portfolio of products from KG Bio in the field of immuno-oncology," he said.
According to him, cooperation with Henlius will lead to the development of innovative, high-quality and affordable biological products for consumers in Indonesia and Southeast Asia.
On the other hand, Scott Liu, Co-Founder, President and Chief Executive Officer of Henlius said that the experience and network of KG Bio and Kalbe in Southeast Asia will assist the development and commercialization of HLX10 in the global market. to say. "We also welcome the collaboration with KG Bio and Kalbe," he said. (LK/AR)